In This Issue:
Investor Q&A; Key Regulatory Issues for Strategic Life Sciences Partnerships in China; Compulsory Patent Licensing in China; and New Developments on the “Patentable Subject Matter” Requirement of U.S. Patent Law.
Excerpt from Investor Q&A -
Dr. Dan Zhang has more than ten years of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO company based in South East Asia and China. Previously, Dr. Zhang was the head of clinical development and global safety assessment at Sigma-Tau Research Inc., a Vice President at the Quintiles Transnational Corp., and the Chairman of the Board at Quintiles Medical Development (Shanghai) Company Ltd.
Please see full issue below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Biotechnology, China, Compulsory Licenses, Drug Manufacturers, Foreign Copyright Protection, Foreign Investment, Licenses, Life Sciences, Patent-Eligible Subject Matter, Patents, Pharmaceutical
Published In: Intellectual Property Updates, International Trade Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Morrison & Foerster LLP | Attorney Advertising